Health

Results: 421-432 of 7367

Crown Bioscience Achieves Second CLIA Certification of 2025 at Suzhou Laboratory

Novotech Maps Global Growth in Radiopharmaceutical Trials

Sales of Leqembi® totaled 18 billion yen in the third quarter 2025

Thousands with undiagnosed hepatitis and HIV found in A&E testing

Enzymatica AB: Quarterly report Q3/2025: Strong development in Sweden and continued focus on international expansion

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial Results

PR Newswire associated0

Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its Payload-Linker Platform and Bioconjugate Capabilities

Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results

PR Newswire associated0

Jungbunzlauer Tricalcium Citrate Excipient Demonstrates Outstanding Results in Direct Compression Study

Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol Shin, CSO, LOTTE BIOLOGICS; James Park, CEO, LOTTE BIOLOGICS; Joerg Ahlgrimm, CEO, SK pharmteco; Andy Fenny, CCO, SK pharmteco; Olivia Boyce, Global Head of Proposals, SK pharmteco; Shiuk Lee, CSO, SK pharmteco; Steve Barr, Head of Small Molecule, SK pharmteco.

SK pharmteco and LOTTE BIOLOGICS Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities

Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®